Creative Planning’s Viridian Therapeutics VRDN Stock Holding History

Creative Planning’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Buy	18,108 +5,007	+38%	+$80.7K	﹤0.01%	3497
2026 Q1	$256K	Buy	13,101 +162	+1%	+$4.81K	﹤0.01%	3545
2025 Q4	$403K	Buy	12,939 +21	+0.2%	+$576	﹤0.01%	3022
2025 Q3	$279K	Buy	12,918 +110	+0.9%	+$1.98K	﹤0.01%	3203
2025 Q2	$179K	Buy	+12,808	New	+$174K	﹤0.01%	3265
2020 Q4	–	Sell	-1,530	Closed	-$18K	–	2472
2020 Q3	$18K	Buy	1,530 +267	+21%	+$3.98K	﹤0.01%	1993
2020 Q2	$21K	Buy	+1,263	New	+$14.3K	﹤0.01%	1826
2017 Q2	–	Sell	-44	Closed	-$8K	–	4846
2017 Q1	$8K	Hold	44	–	–	﹤0.01%	3741
2016 Q4	$3K	Hold	44	–	–	﹤0.01%	4176
2016 Q3	$5K	Sell	44 -15	-25%	-$1.67K	﹤0.01%	3903
2016 Q2	$6K	Hold	59	–	–	﹤0.01%	3563
2016 Q1	$7K	Hold	59	–	–	﹤0.01%	3424
2015 Q4	$10K	Hold	59	–	–	﹤0.01%	3316
2015 Q3	$12K	Buy	59 +15	+34%	+$5.27K	﹤0.01%	3092
2015 Q2	$22K	Buy	+44	New	+$17.8K	﹤0.01%	1066

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Creative Planning's VRDN Position: Q2 2026 in Review

Creative Planning increased its Viridian Therapeutics (VRDN) stake by 38% in Q2 2026, buying an estimated $80.7K and bringing the position to 18,108 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #3497.

Creative Planning first reported a position in VRDN in Q2 2015 and has held it in 15 quarters since. The position peaked at $403K in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Creative Planning held 18,108 shares of Viridian Therapeutics worth $333K as of Q2 2026.
Creative Planning bought 5,007 Viridian Therapeutics shares in Q2 2026, an estimated $80.7K.
Viridian Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3497 holding.
Creative Planning first reported a position in Viridian Therapeutics in Q2 2015 and has held it in 15 quarters since.
Creative Planning's Viridian Therapeutics position peaked at $403K in Q4 2025.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.